Jump to content

User:Mattsnod/sandbox: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Mattsnod (talk | contribs)
64 edits
edits to the body copy
m disable categories while still a draft, per WP:USERNOCAT, by converting them to links: "[[Category:" → "[[:Category:"
 
(19 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Infobox company
{{Infobox drug
| type = mab
| name = Syneos Health
| logo =
| image =
| alt =
| type = [[Public company|Public]]
| mab_type = mab<!-- mab, Fab, F(ab')2, Fab', scFv, di-scFv, 3funct, clFab, BiTE -->
| traded_as = {{NASDAQ|SYNH}}
| source = zu
| industry = [[Contract Research Organization]], [[Pharmaceutical]] Service Consulting, [[Public Relations]], [[Biopharmaceutical]], [[Advertising]], [[Marketing]]
| target = [[PD-1]]
| foundation = {{Start date|2018}}<ref>{{Cite web|date=4 January 2018|title=INC Research/inVentiv Health Becomes Syneos Health|url=https://globenewswire.com/news-release/2018/01/04/1283447/0/en/INC-Research-inVentiv-Health-Becomes-Syneos-Health.html|publisher=GlobeNewswire}}</ref>
<!-- Clinical data -->

| pronounce =
(inVentiv Health: 1999)
| tradename =
(INC Research: 1998)
| Drugs.com =
| location = [[Raleigh, North Carolina|Raleigh]], [[North Carolina]]<ref>{{Cite web|date=31 December 2017|title=Syneos Health SEC Form 10-K|url=http://www.investor.syneoshealth.com/static-files/9469ea8d-86d3-4e05-a98d-30e5d347d8b8|publisher=Syneos Health|p=53}}</ref>
| MedlinePlus =
| key_people = Alistair Macdonald, CEO<ref>{{Cite web|date=31 December 2017|title=Syneos Health SEC Form 10-K|url=http://www.investor.syneoshealth.com/static-files/9469ea8d-86d3-4e05-a98d-30e5d347d8b8|publisher=Syneos Health|p=25}}</ref>
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| products =
| pregnancy_US = <!-- A/B/C/D/X -->
| revenue =
| pregnancy_category=
| num_employees = 21,000<ref>{{Cite web|date=31 December 2017|title=Syneos Health SEC Form 10-K|url=http://www.investor.syneoshealth.com/static-files/9469ea8d-86d3-4e05-a98d-30e5d347d8b8|publisher=Syneos Health|p=4}}</ref>
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| website = {{URL|syneoshealth.com}}
| legal_AU_comment =
| net income =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| Areas served = Worldwide
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_NZ = <!--Class A, B, C -->
| legal_status =
| routes_of_administration =
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 1858168-59-8
| ATC_prefix = none
| ATC_suffix =
| PubChem =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0KVO411B3N
| DrugBank =
| KEGG = D11487
| ChemSpiderID = none
| synonyms = {{unbulleted list |BGB-A317<ref name="Lymphoma News Today 27Jul2018" /> |Tisle<ref name="Motley Fool 2018 Erickson" /> }}
}}
}}
'''Syneos Health''' is a global contract research organization (CRO) and contract commercialization organization (CCO) headquartered in Raleigh, North Carolina<ref>{{Cite web|url=http://www.investor.syneoshealth.com/static-files/9469ea8d-86d3-4e05-a98d-30e5d347d8b8|title=Syneos Health SEC Form 10-K|last=|first=|date=31 December 2018|website=Syneos Health|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. The company, created through the merger of INC Research and inVentiv Health, on August 1, 2018 has more than 21,000 employees and provides services in more than 110 countries.


'''Tislelizumab'''<ref>{{cite web|url=https://bciq.biocentury.com/products/bgb-a317|title=tislelizumab (BGB-A317)|website=BioCentury – BCIQ}}</ref><ref>{{cite web|url=https://beigeneltd.gcs-web.com/investor-overview|title=Investor Overview|website=BeiGene LTD}}</ref> ('''BGB-A317''') is a humanized [[monoclonal antibody]] directed against [[PD-1]].<ref name=ASCO-2016>{{cite web|url=https://meetinglibrary.asco.org/record/125804/abstract|title=Meeting Library - Meeting Library|website=meetinglibrary.asco.org}}</ref> It prevents PD-1 from binding to the ligands [[PD-L1]] and [[PD-L2]] (hence it is a [[checkpoint inhibitor]]). It is being investigated as a treatment for advanced solid [[tumors]].<ref name=ASCO-2016/>
The company provides clinical development and commercial solution offerings to biopharmaceutical customers – spanning from phase I-IV clinical development services, functional service clinical development services to public relations, advertising, market access solutions and consulting services.


It is designed to bind less to [[Fc gamma receptor]]s.<ref name="SI-2017">{{cite web|title=BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer|url=https://www.streetinsider.com/Corporate+News/BeiGene+(BGNE)+Commences+Pivotal+Trial+of+PD-1+Antibody+BGB-A317+in+China+in+Patients+with+Urothelial+Cancer/13068864.html|publisher=}}</ref>


It is being developed by [[BeiGene]].<ref>{{Cite web|last=|first=|date=2019-06-17|title=Celgene hands PD-1 tislelizumab med back to BeiGene, forfeiting $150M|url=https://www.fiercebiotech.com/biotech/celgene-hands-pd-1-tislelizumab-med-back-to-beigene-forfeiting-150m|url-status=live|archive-url=|archive-date=|access-date=2020-07-01|website=Fierce Biotech}}</ref>
== References ==
{{reflist}}


== Further reading ==
== Medical Uses ==
Tislelizumab was approved by the China [[National Medical Products Administration]] on December 27, 2019 to treat patients with classical [[Hodgkin lymphoma|Hodgkin’s lymphoma]] (cHL) who have received at least two prior therapies<ref>{{Cite web|last=|first=|date=2020-01-02|title=BeiGene scores first China OK with PD-1 — to be manufactured by Boehringer Ingelheim|url=https://endpts.com/beigene-scores-first-china-ok-with-pd-1-to-be-manufactured-by-boehringer-ingelheim/|url-status=live|archive-url=|archive-date=|access-date=2020-07-01|website=Endpoints News|language=en}}</ref> and on April 10, 2020 to treat patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing [[chemotherapy]] or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.<ref>{{Cite web|last=|first=|date=20200414|title=Ploughing through a crowded PD-(L)1 market, BeiGene loads up on promising lung cancer data|url=https://endpts.com/ploughing-through-a-crowded-pd-l1-market-beigene-loads-up-on-promising-lung-cancer-data/|url-status=live|archive-url=|archive-date=|access-date=2020-07-01|website=Endpoints News|language=en}}</ref>


==Clinical trials==
* {{Cite web|url=http://news.centerwatch.com/tag/inventiv-health/|title=inVentiv Health Archives – CenterWatch News Online|date=20 July 2015|website=CenterWatch News Online|accessdate=2015-08-03}}
[[Clinical trial|Clinical trials]] of tislelizumab include:

* Phase 1 trial in patients with advanced solid tumors (NCT02407990)<ref>{{Cite web|title=Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT02407990|access-date=2020-07-03|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with non-small cell lung cancer (NSCLC) (NCT03358875)<ref>{{Cite web|title=Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03358875|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC) (NCT03412773)<ref>{{Cite web|title=Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03412773|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897)<ref>{{Cite web|title=Study of BGB-A317 in Participants With Previously Treated Unresectable HCC - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03419897|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) (NCT03430843)<ref>{{Cite web|title=A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03430843|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747)<ref>{{Cite web|title=A Study Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer. - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03594747|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205)<ref>{{Cite web|title=A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03663205|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889)<ref>{{Cite web|title=Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03736889|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657)<ref>{{Cite web|title=Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03777657|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442)<ref>{{Cite web|title=A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03783442|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986)<ref>{{Cite web|title=Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03924986|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590)<ref>{{Cite web|title=Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Patient With ESCC - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03957590|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977)<ref>{{Cite web|title=Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT03967977|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>
* Phase 2 trial in patients with locally advanced or metastatic urothelial bladder cancer (NCT04004221)<ref>{{Cite web|title=Study of BGB-A317 in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04004221|access-date=2020-07-06|website=clinicaltrials.gov|language=en}}</ref>
* Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716)<ref>{{Cite web|title=Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04005716|access-date=2020-07-01|website=clinicaltrials.gov|language=en}}</ref>

==Pharmacokinetics==
Early phase I clinical trial results give an [[elimination half-life]] of 11 to 17 days.<ref name=ASCO-2016/>

== References ==
{{reflist |refs=

<ref name="Lymphoma News Today 27Jul2018">{{cite news |url=https://lymphomanewstoday.com/2018/07/27/beigene-treatment-candidate-eliminates-some-hodgkins-lymphoma-tumors/ |title=BeiGene’s Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin’s Patients in Phase 2 Trial |last=Lopes |first=Jose Marques |date=27 July 2018 |work=Lymphoma News Today |publisher=BioNews Services |location=Philadelphia, Pennsylvania, United States }}</ref>

<ref name="Motley Fool 2018 Erickson">{{Cite web|url=https://www.fool.com/investing/2018/07/03/3-reasons-beigene-needs-to-be-on-your-investing-ra.aspx|title=3 Reasons BeiGene Needs to Be on Your Radar|last=Erickson|first=Simon|date=July 3, 2018|website=The Motley Fool|url-status=live|archive-url=|archive-date=|access-date=2 Nov 2019}}</ref>

}}


{{monoclonals for immune system}}
[[Category:Biotechnology companies]]
[[Category:Companies based in Massachusetts]]
[[:Category:Monoclonal antibodies]]
[[Category:Contract research organizations]]
[[:Category:Experimental drugs]]
[[Category:Companies listed on NASDAQ]]

Latest revision as of 03:09, 21 August 2020

Mattsnod/sandbox
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPD-1
Clinical data
Other names
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

Tislelizumab[3][4] (BGB-A317) is a humanized monoclonal antibody directed against PD-1.[5] It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.[5]

It is designed to bind less to Fc gamma receptors.[6]

It is being developed by BeiGene.[7]

Medical Uses

[edit]

Tislelizumab was approved by the China National Medical Products Administration on December 27, 2019 to treat patients with classical Hodgkin’s lymphoma (cHL) who have received at least two prior therapies[8] and on April 10, 2020 to treat patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.[9]

Clinical trials

[edit]

Clinical trials of tislelizumab include:

  • Phase 1 trial in patients with advanced solid tumors (NCT02407990)[10]
  • Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with non-small cell lung cancer (NSCLC) (NCT03358875)[11]
  • Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC) (NCT03412773)[12]
  • Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897)[13]
  • Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) (NCT03430843)[14]
  • Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747)[15]
  • Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205)[16]
  • Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889)[17]
  • Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657)[18]
  • Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442)[19]
  • Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986)[20]
  • Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590)[21]
  • Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977)[22]
  • Phase 2 trial in patients with locally advanced or metastatic urothelial bladder cancer (NCT04004221)[23]
  • Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716)[24]

Pharmacokinetics

[edit]

Early phase I clinical trial results give an elimination half-life of 11 to 17 days.[5]

References

[edit]
  1. ^ Lopes, Jose Marques (27 July 2018). "BeiGene's Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin's Patients in Phase 2 Trial". Lymphoma News Today. Philadelphia, Pennsylvania, United States: BioNews Services.
  2. ^ Erickson, Simon (July 3, 2018). "3 Reasons BeiGene Needs to Be on Your Radar". The Motley Fool. Retrieved 2 Nov 2019.{{cite web}}: CS1 maint: url-status (link)
  3. ^ "tislelizumab (BGB-A317)". BioCentury – BCIQ.
  4. ^ "Investor Overview". BeiGene LTD.
  5. ^ a b c "Meeting Library - Meeting Library". meetinglibrary.asco.org.
  6. ^ "BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer".
  7. ^ "Celgene hands PD-1 tislelizumab med back to BeiGene, forfeiting $150M". Fierce Biotech. 2019-06-17. Retrieved 2020-07-01.{{cite web}}: CS1 maint: url-status (link)
  8. ^ "BeiGene scores first China OK with PD-1 — to be manufactured by Boehringer Ingelheim". Endpoints News. 2020-01-02. Retrieved 2020-07-01.{{cite web}}: CS1 maint: url-status (link)
  9. ^ "Ploughing through a crowded PD-(L)1 market, BeiGene loads up on promising lung cancer data". Endpoints News. 20200414. Retrieved 2020-07-01. {{cite web}}: Check date values in: |date= (help)CS1 maint: url-status (link)
  10. ^ "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-03.
  11. ^ "Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  12. ^ "Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  13. ^ "Study of BGB-A317 in Participants With Previously Treated Unresectable HCC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  14. ^ "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  15. ^ "A Study Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer. - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  16. ^ "A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  17. ^ "Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  18. ^ "Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  19. ^ "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  20. ^ "Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  21. ^ "Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Patient With ESCC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  22. ^ "Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.
  23. ^ "Study of BGB-A317 in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-06.
  24. ^ "Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-01.

Category:Monoclonal antibodies Category:Experimental drugs

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=User:Mattsnod/sandbox&oldid=974099895"